In the Once Weekly Interferon for MS (OWIMS) trial, IFNß-1a was administered at doses of 22 and 44µg subcutaneously once weekly. [21] The primary outcome measure was the number of combined ...

Up to 50% of patients with multiple sclerosis (MS) relapse despite receiving treatment with interferon β (IFN-β). Two recent studies have investigated pharmacological and genetic markers that ...